Epigenetics Market

Epigenetics Market Size, Growth (2022 to 2027)

As per our report, the global epigenetics market size is predicted to grow from USD 892.6 million in 2022 to USD 1706.6 million by 2027, showcasing a CAGR of 13.84 % during the forecast period.

Epigenetics is the study of change in behavior of organisms by modification of gene expression rather than a change in genetic code itself. Genes will get turned off or turned on depending on the circumstances, interactions, etc. These turning on and off of genes differ in most humans, making humans unique. Some of these traits are passed down to future generations as heritable traits. The study of this entire mechanism is called Epigenetics. For instance, epigenetic change is DNA methylation, where the addition of a methyl group to part of the DNA molecule prevents certain gene expressions. This type of epigenetic change of DNA methylation is associated with cancer development and progression. Scientist claim that the genetical changes such a tumor suppression helps prevent cancer from one generation to other. In many other aspects, epigenetics methodology contributes to helping diagnose diseased conditions earlier and prevent them for future generations. 

MARKET DRIVERS:

The rising prevalence of cancer and technological advancements in cancer treatment are majorly driving the growth of the Global Epigenetics Market.

Globally, the number of individuals who have Cancer has increased significantly. There is about 18 million population suffering from Cancer. The primary cancer types are Cancer of the oral cavity and pharynx, Breast Cancer, Bowel Cancer, Lung cancer, prostate cancer. Similarly, in that, 33% caused because of smoking habits. Obesity and Overweight is the second biggest cause of cancer after smoking.

The origin and progression of cancer are associated with epigenetic changes such as dysregulation of DNA methylation. Epigenetics offers new ways to develop therapeutic approaches to reverse cancer dysregulation. Several cancer research trials are currently underway using epigenetics techniques; massive investments are being made to support them.

The global epigenetics market is further driven by the increasing funding in R&D and the increasing frequency of research activities in this field.

MARKET RESTRAINTS:

The dearth of the skilled person in utilizing the systems in diagnostic centers and the high costs associated with the instruments and treatment options are the major factors restraining the growth of the epigenetics market.

Difficulties in getting approvals from government organizations for innovative products, lack of reimbursement schemes by the government, especially in undeveloped countries, and lack of awareness of different epigenetic techniques in the rural areas are further expected to limit the market growth. 

Impact of COVID-19 on the global epigenetics market:

The SARS-CoV-2 reagent is responsible for causing COVID 19 worldwide. Millions of people are affected by the infection, and almost all sectors are involved, including the medical field. Epigenetics plays a vital role in the inflexibility of symptoms in COVID 19. Efforts focus on recognizing and advancing efficient pharma plans, and precision medicine holds a commitment to a voluminous increase in guarding the epigenetic variability in SARS-Cov-2 infection. The epigenetic mechanisms are an essential part of the pathophysiology and illness severity of COVID-19. The structure and anatomy have been recognized in the SARS-CoV-2, also among the other infections. Scientists are researching how the coronavirus impacts the administering and controlling of the human genome. For example, the Icahn School of Medicine at Mount Sinai and other medical schools advanced an epigenetic test that permits early recognition of the new coronavirus leading to COVID-19. Epigenetics of the COVID-19 infection helps clinicians identify the virus more appropriately, evaluate the risk and severity of the diseases, and personalize treatment options across varying patient profiles. Recent research of epigenetic alterations could better unveil predicting makers, new targets, and the associated mechanisms of SARS-CoV-2 and COVID-19.

REPORT COVERAGE:

This research report on the Global Epigenetics Market has been segmented and sub-segmented based on the anatomical location, consumable type, and Region.

Epigenetics Market - By Product:

• Enzymes
• Instruments & Consumable
• KITS
• Reagents

In 2020, the enzymes segment held the highest shares in the global market based on the product, followed by the Instruments & Consumables segment. Growing awareness over the availability of different techniques is elevating the demand of this segment. However, the Kits and reagents segment is projected to grow in the forecast period significantly.

Epigenetics Market - By Research Area:

• Developmental Biology
• Oncology
• Drug Delivery

Throughout last year, Oncology led the overall market, accounting for 69.6% of total revenue. Growing the prevalence of cancer worldwide is projected to be a high impact-making factor on the market, along with increased cancer deaths. Additionally, due to the introduction of new products and potential future promotion of goods already in the pipeline, this segment is expected to gain a significant revenue share throughout the forecast period.

The developmental biology segment is expected to shine well in the market due to the increasing scale of research centers. COVID-19 is impacting largely on the growth of this segment as researchers are focused on developing a vaccine for this novel disease. The oncology segment also has a significant growth rate from the past few years. On-going research on next-generation sequencing is lavishing the growth rate of this segment. Drug delivery is to have slow growth opportunities in the forecast period. 

Epigenetics Market - By Enzymes:

• DNA-Modifying Enzymes
• Protein-Modifying Enzymes
• RNA-Modifying Enzymes

Based on enzymes, the DNA-Modifying Enzymes segment accounted for most of the shares in the market in 2019. Increasing support from the government authorities through funds is a major factor fueling the demand of the market. Protein-modifying enzymes are next to DNA-modifying enzymes in holding the highest shares of the market. Prevalence to develop innovative drugs or vaccines to promote quality treatment procedures across the world greatly influences the growth rate of the market. The RNA-modifying enzymes segment is expected to have the highest CAGR in the coming years. 

Epigenetics Market - By Instruments & Consumables:

• Mass Spectrometers
• Next-Generation Sequencers
• qPCR
• Sonicators

The qPCR segment was the market leader among different types of instruments and consumables and held the highest shares of the market in 2019. Raising awareness through campaigns and digital platforms in the medical sector impacts the growth of the market. Next-generation sequences are following the qPCR segment with the increasing studies on genomic. Mass spectrometers segment and sonicators segments are to have a prominent growth rate in foreseen years.

Epigenetics Market - By KITS:

• Bisulfite Conversion KITS
• Chip-Sequence KITS
• RNA Sequencing KITS
• Whole-Genome Amplification KITS
• 5-HMC and 5-MC Analysis KITS

Based on KITS, the Bisulfate conversion kits segment is having the highest shares of the market. Public and private organizations are investing in the biotechnology field, which is a common factor for the market to grow. Chip sequence kits and RNA sequencing kits are next to the bisulfate conversion kits segment owing to the growing demand to promote high-quality services to the patients. Whole-genome amplification kits and 5-HMC and 5-MC Analysis KITS segments are inclined to have the highest growth rate in a few years.

Epigenetics Market - By Reagents:

• Antibodies
• Buffers
• Histones
• Magnetic Beads
• Primers

Based on reagents, the antibodies reagents segment is ruling with dominant shares of the market. Due to rising cases of COVID-19, clinical trials are put on the fast track to develop a vaccine. This is propelling the demand for this segment to the extent. Buffers and histones segments are expected to lead the market shares in the coming years. Constant economic growth in both developed and developing countries is ascribed to bolster the demand of these segments. The magnetic beads and primers segment is to have a steady pace in the forecast period.

Epigenetics Market - By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• The Middle East and Africa

Based on Region, North America dominated the global market in 2019. The growth of the epigenetics market in North America is majorly driven by the massive presence of major players in North America; the government makes significant investments for research and development and rapid healthcare infrastructure development. In North America, there is a huge demand for insulin, antibodies, mammalian proteins, and vaccines to produce industrially and are expected to help the market climb new growth heights. In the future, the North American market will have many opportunities for market leaders and new players.    

In Europe, the epigenetics market is expected to have promising growth in the coming years. More than 3.7 million new cases and 1.9 million cancer deaths occur in the European Region as per the data given by the WHO. The European Region is the second-largest region in the global epigenetics market, which has the highest mortality rate of cancer. The rising patient count and cancer incidence are expected to propel the market growth in this region.

The Asia-pacific market is expected to grow at the highest CAGR during the forecast period due to developing countries like India and China and increasing R&D spending.

KEY MARKET PARTICIPANTS AND SHARE INSIGHTS:

Companies playing a leading role in the global epigenetics market profiled in this report are Abcam PLC, Illumina, Inc., QIAGEN N.V., Merck & Co, New England Biolabs, Inc., Sigma-Aldrich Corporation, Thermo Fisher Scientific, Inc., Active Motif, Diagenode, Inc. and Zymo Research Corporation.

KEY MARKET HAPPENINGS:

• In February 2018, QIAGEN began epigenetic breast cancer screening in Europe February 2018. 
• In November 2015, Abcam completed the acquisition of AxioMx to access new growth opportunities and expand the leadership of antibodies. The expansion of its business in the global market for epigenetics.
• In April 2014, Roche and Oryzon Genomics SA announced a global partnership to study, develop and market Lysine Specific Demethylase-1 (LSD1; KDM1A) inhibitors, an epigenetic modulator that controls gene expression.